Nuclear, compared with combined nuclear and cytoplasmic expression of maspin, is linked in lung adenocarcinoma to reduced VEGF-A levels and in Stage I, improved survival

被引:27
作者
Frey, Amy
Soubani, Ayman O. [2 ]
Adam, Abdulgadir K. [2 ]
Sheng, Shijie
Pass, Harvey I. [3 ,4 ]
Lonardo, Fulvio [1 ]
机构
[1] Wayne State Univ, Karmanos Canc Inst, Dept Pathol, Harper Univ Hosp, Detroit, MI 48201 USA
[2] Wayne State Univ, Div Pulm Allergy Crit Care & Sleep Med, Dept Internal Med, Harper Univ Hosp, Detroit, MI 48201 USA
[3] NYU, Ctr Comprehens Canc, NCI, Div Thorac Surg,Dept Cardiothorac Surg, New York, NY USA
[4] NYU, Ctr Comprehens Canc, NCI, Div Thorac Oncol,Dept Cardiothorac Surg, New York, NY USA
关键词
lung adenocarcinoma; maspin; p53; prognosis; Stage I; subcellular localization; VEGF-A; TUMOR-SUPPRESSOR GENE; BREAST-CANCER; PULMONARY ADENOCARCINOMA; PROGNOSTIC-SIGNIFICANCE; EPITHELIAL-CELLS; DOWN-REGULATION; POOR-PROGNOSIS; MESSENGER-RNA; PROGRESSION; CARCINOMA;
D O I
10.1111/j.1365-2559.2009.03260.x
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
To evaluate whether there is a correlation between the subcellular localization of maspin and the histological, molecular and biological features of pulmonary adenocarcinoma, particularly addressing the hypothesis that the tumour inhibitor properties of maspin may be linked to a nuclear, compared with a combined nuclear and cytoplasmic expression pattern. The subcellular expression of maspin was determined in 80 resected pulmonary adenocarcinomas (Stage I, 46; Stage II, 10; Stage III, 20; Stage IV, 4) and correlated with histological grade, proliferative rate, p53 expression, vascular endothelial growth factor (VEGF)-A levels, and prognosis (mean follow-up of 41.5 months). Cases with nuclear (N) maspin (n = 47), compared with the [N + cytoplasmic (C)] group (n = 28), showed lower (P <= 0.05): histological grade, proliferative rate, p53 expression and VEGF-A levels. Cox multivariate analysis revealed in stage I adenocarcinomas (N) maspin as the only predictor of improved survival. (N) maspin selects lung adenocarcinomas with distinct molecular and clinical features, supporting the hypothesis that its tumour inhibitor properties may be linked to its nuclear localization.
引用
收藏
页码:590 / 597
页数:8
相关论文
共 35 条
[1]   Biological functions of maspin [J].
Bailey, Caleb M. ;
Khalkhali-Ellis, Zhila ;
Seftor, Elisabeth A. ;
Hendrix, Mary J. C. .
JOURNAL OF CELLULAR PHYSIOLOGY, 2006, 209 (03) :617-624
[2]   Prognostic value of maspin mRNA expression in ERα-positive postmenopausal breast carcinomas [J].
Bièche, I ;
Girault, I ;
Sabourin, JC ;
Tozlu, S ;
Driouch, K ;
Vidaud, M ;
Lidereau, R .
BRITISH JOURNAL OF CANCER, 2003, 88 (06) :863-870
[3]   Maspin expression in early oral tongue cancer and its relation to expression of mutant-type p53 and vascular endothelial growth factor (VEGF) [J].
Cho, Jae Hoon ;
Kim, Hyung-Seok ;
Park, Chang-Soo ;
Kim, Jin Kook ;
Jung, Kwang-Yoon ;
Shin, Bong-Kyoung ;
Kim, Han-Kyum .
ORAL ONCOLOGY, 2007, 43 (03) :272-277
[4]  
Czerwenka KF, 2001, CANCER DETECT PREV, V25, P268
[5]   Regulation of tumor suppressors by nuclear-cytoplasmic shuttling [J].
Fabbro, M ;
Henderson, BR .
EXPERIMENTAL CELL RESEARCH, 2003, 282 (02) :59-69
[6]  
Han H, 2001, ANN SURG ONCOL, V8, P72, DOI 10.1245/aso.2001.8.1.72
[7]   From the membrane to the nucleus and back again: bifunctional focal adhesion proteins [J].
Hervy, Martial ;
Hoffman, Laura ;
Beckerle, Mary C. .
CURRENT OPINION IN CELL BIOLOGY, 2006, 18 (05) :524-532
[8]   Prognostic significance of the tumor suppressor gene maspin in non-small cell lung cancer [J].
Hirai, K ;
Koizumi, K ;
Haraguchi, S ;
Hirata, T ;
Mikami, I ;
Fukushima, M ;
Yamagishi, S ;
Kawashima, T ;
Okada, D ;
Shimizu, K ;
Kawamoto, M .
ANNALS OF THORACIC SURGERY, 2005, 79 (01) :248-253
[9]   Maspin gene expression is a significant prognostic factor in resected non-small cell lung cancer (NSCLC) - Maspin in NSCLC [J].
Katakura, H ;
Takenaka, K ;
Nakagawa, M ;
Sonobe, M ;
Adachi, M ;
Ito, S ;
Wada, H ;
Tanaka, F .
LUNG CANCER, 2006, 51 (03) :323-328
[10]   Maspin: The new frontier [J].
Khalkhali-Ellis, Zhila .
CLINICAL CANCER RESEARCH, 2006, 12 (24) :7279-7283